Blockers reduce the functions of ion channels, membrane transporters, or nonspecific molecular interactions and can be used to investigate transmembrane currents, neurotransmitter transport, and interference in immunoassays. Their modes of action include pore blockade, gating modulation, state-dependent binding, transport inhibition, and neutralization of interfering factors.

Keywords: blockers; ion channels; NaV; Kv; CaV; HCN; TRP; PANX1; EAAT; heterophilic antibodies; HAMA; immunoassays

1 Basis of Blocker Action

1.1 Different Types of “Blockade” Correspond to Different Molecular Processes

Ion-channel blockers primarily reduce transmembrane currents carried by Na⁺, K⁺, Ca²⁺, or Cl⁻; membrane-transporter blockers inhibit substrate binding or transport cycles; intracellular signaling blockers act on second messengers or protein kinases; blocking reagents used in immunoassays bind interfering substances such as heterophilic antibodies, human anti-mouse antibodies, or rheumatoid factors. Although all these products may be described as blockers, their direct targets and resulting biological effects are different.

1.2 Major Modes of Ion-Channel and Membrane-Transport Blockade

(1) Pore Blockade

Pore blockers directly occupy the ion-conduction pathway and reduce ion flux through open channels. The blocking site may be located within the intracellular pore cavity or at the extracellular pore entrance. For example, Iberiotoxin binds BK/KCa1.1 channels from the extracellular side and reduces K⁺ currents, whereas certain NaV blockers enter the channel from the intracellular side. Pore blockade is generally manifested directly as a reduction in the corresponding ionic current.

(2) Gating Modulation

Gating modulators do not necessarily enter the ion-conducting pore but instead bind voltage-sensing structures or other gating-associated regions, altering channel activation, inactivation, or open probability. ProTx-II acts on voltage-sensing structures associated with NaV1.7, whereas Phrixotoxin-1 affects Kv4 channel gating. These molecules can be used to investigate the relationship between voltage sensors and pore opening.

(3) State-Dependent Blockade

Channels can adopt different conformations, including closed, open, and inactivated states, and certain blockers have higher affinity for the open or inactivated state. Lidocaine more readily produces blockade during repeated NaV opening and inactivation, so its effects are generally more pronounced under high-frequency stimulation than under resting conditions. State dependence allows the same blocker to produce different effects under different conditions of cellular electrical activity.

(4) Transporter Blockade

Membrane transporters such as EAATs complete transport by binding substrates and undergoing conformational transitions rather than by forming continuously open ion pores. TFB-TBOA binds glutamate transporters and restricts the normal transport cycle, slowing extracellular glutamate clearance; it therefore blocks a membrane-transport process.

2 Voltage-Gated Ion-Channel Blockers

2.1 NaV-Channel Blockade

(1) NaV1.7 and Sensory Thresholds

Voltage-gated sodium channels (NaV) open rapidly following membrane depolarization, and Na⁺ influx forms the rapid rising phase of the action potential. NaV1.7 is encoded by SCN9A and is abundantly expressed in peripheral sensory neurons, where it amplifies depolarizing signals approaching the action-potential threshold; changes in its function can therefore affect the ability of nociceptive neurons to reach the firing threshold. ProTx-II primarily inhibits channel activation by modulating voltage-sensing structures in NaV1.7, while GX 201 can also be used as a NaV1.7-blocking research tool to evaluate the role of NaV1.7 in sensory-neuron excitation and pain signaling.

(2) NaV1.8 and Sustained Firing

NaV1.8 is primarily distributed in peripheral nociceptive neurons and is a tetrodotoxin-resistant NaV subtype that plays an important role in action-potential maintenance and repetitive firing. PF-01247324 can be used in NaV1.8-blockade studies. Separate interventions targeting NaV1.7 and NaV1.8 can be used to distinguish the respective contributions of threshold amplification and sustained firing to nociception.

(3) Lidocaine and State-Dependent NaV Blockade

Lidocaine has relatively high affinity for NaV channels in their open and inactivated states. During high-frequency firing, NaV channels repeatedly enter open and inactivated states, causing blockade to increase progressively; the resulting reduction in Na⁺ current suppresses action-potential propagation. This mechanism provides an important molecular basis for its local anesthetic activity.

(4) Multichannel Blockade and Neuronal Excitability

Certain NaV blockers also act on other ion channels. Sipatrigine can affect NaV channels and other ionic currents, making it more suitable as a research tool for neuronal excitability and multichannel modulation; phenotypic changes following its administration therefore cannot be attributed to a single NaV subtype alone.

2.2 K⁺-Channel Blockade

(1) Kv4 and A-Type K⁺ Currents

Kv4.2 and Kv4.3 contribute to rapidly activating and rapidly inactivating A-type K⁺ currents. These currents provide transient K⁺ efflux during the early phase of the action potential and regulate neuronal dendritic excitability, action-potential intervals, and repetitive firing. Phrixotoxin-1 primarily acts on Kv4.2 and Kv4.3 and can reduce Kv4-associated currents by altering channel gating.

(2) IKs and Cardiac Repolarization

The slowly activating delayed-rectifier K⁺ current IKs is primarily formed by KCNQ1, KCNE1, and associated components and provides an outward K⁺ current during cardiac action-potential repolarization. HMR 1556 reduces IKs and can be used to investigate its contribution to cardiac repolarization and action-potential duration.

(3) Kv1.3 and Margatoxin

Kv1.3 participates in the regulation of membrane potential in immune cells and certain neural cells and is coupled to Ca²⁺ signaling. Margatoxin blocks Kv1.3 with high affinity but also potently inhibits Kv1.2 and is therefore not a Kv1.3-specific tool.

(4) KCa1.1 and KCa3.1

KCa1.1/BK channels are regulated by both membrane potential and intracellular Ca²⁺ and can generate substantial K⁺ efflux when intracellular Ca²⁺ increases. Iberiotoxin blocks BK channels with high affinity and can be used to analyze the contribution of BK channels to membrane repolarization and Ca²⁺-dependent feedback regulation. KCa3.1 is an intermediate-conductance Ca²⁺-activated K⁺ channel, and Senicapoc reduces K⁺ efflux by blocking KCa3.1/Gardos channels; it can be used to investigate erythrocyte hydration, volume regulation, and KCa3.1 function in other cell types.

2.3 CaV-Channel Blockade

(1) L-Type Ca²⁺ Channels

L-type Ca²⁺ channels are high-voltage-activated channels that play an important role in Ca²⁺ entry into cardiac and smooth muscle cells. By blocking L-type Ca²⁺ channels, Nifedipine reduces Ca²⁺ influx and weakens vascular smooth-muscle contraction; it is therefore commonly used to investigate L-type Ca²⁺ currents and their relationship with contractile function.

(2) CaV2.2 and Neurotransmitter Release

CaV2.2 is an N-type Ca²⁺ channel that plays an important role at presynaptic terminals. When an action potential reaches the nerve terminal, CaV2.2 opens, producing a local increase in Ca²⁺ that triggers synaptic-vesicle fusion. Blockade of CaV2.2 reduces presynaptic Ca²⁺ entry and neurotransmitter release, so CaV2.2 blockers can be used to investigate synaptic transmission and pain-related neural circuits.

(3) CaV3.x and Low-Threshold Firing

CaV3.1, CaV3.2, and CaV3.3 are T-type Ca²⁺ channels that open at relatively negative membrane potentials and generate low-threshold Ca²⁺ currents. Z 944 and TTA-P2 can be used in CaV3.x research, while ABT 639 blocks CaV3.2 and CaV3.1. T-type Ca²⁺ channels are closely associated with rhythmic firing, sensory-neuron excitation, and regulation of pain signaling.

2.4 HCN4 and the Cardiac Pacemaker Current

HCN channels gradually open during membrane hyperpolarization. In the sinoatrial node, the HCN4-mediated If current contributes to spontaneous diastolic depolarization and affects the timing of the next action potential. By reducing the HCN-associated If current, Ivabradine slows spontaneous diastolic depolarization and decreases heart rate, making it a representative example of achieving a clinical pharmacological effect through selective modulation of a specific physiological current.

3 Blockade of TRP-, PANX1-, and Cl⁻-Related Pathways

3.1 TRP-Channel Blockade

(1) TRPV1 and Nociception

TRPV1 can be activated by high temperature, acidic environments, capsaicin, and other stimuli, causing Na⁺ and Ca²⁺ influx into nociceptive neurons. AC 4 is a TRPV1-associated optically controlled blocking tool that combines light stimulation with channel-function modulation and can be used for spatiotemporal control of TRPV1 activity.

(2) TRPC Channels and Ca²⁺ Signaling

The TRPC family participates in nonselective cation entry following receptor activation. Clemizole and related products can be used in TRPC-channel blockade studies to analyze TRPC-mediated Ca²⁺ entry, membrane excitability, and associated signaling processes. Because the pharmacological profiles of different TRPC subtypes overlap, a phenotype produced by a single blocker cannot directly identify the specific TRPC subtype involved.

(3) Multitarget Channel Modulators

Flufenamic acid can affect certain TRP channels, Ca²⁺-activated Cl⁻ channels, and connexin-associated channels and is therefore a typical multitarget membrane-channel modulator. Molecules of this type are suitable for determining whether a particular membrane-channel process contributes to a phenotype, but the specific target must still be validated using more selective blockers or genetic methods.

3.2 PANX1 and ATP Release

PANX1 can form large-pore channels in the plasma membrane and participates in the release of ATP and other small molecules. Extracellular ATP subsequently acts on purinergic receptors such as P2X and P2Y, linking PANX1 opening to inflammation, pain, and paracrine signaling.

10Panx is a PANX1-associated mimetic peptide blocker that reduces PANX1-channel function and ATP release and can be used to investigate the PANX1–ATP signaling axis. PANX1 channels and classical cell–cell gap junctions formed by connexins are not the same structural system and therefore cannot be considered equivalent solely because a product is described as a “gap-junction-blocking peptide.”

3.3 Cl⁻-Related Blocking Tools

DIDS and flufenamic acid can both affect Cl⁻-related currents or anion transport, but they have broad activity profiles. DIDS acts on multiple anion-transport proteins and certain Cl⁻ channels, while flufenamic acid affects not only Ca²⁺-activated Cl⁻ currents but also TRP- and connexin-associated channels. These products are therefore more suitable for determining whether a process contains a Cl⁻-dependent component than for identifying a specific Cl⁻-channel subtype based solely on drug sensitivity.

4 Blockade of Membrane Transport and Intracellular Signaling

4.1 EAATs and Glutamate Clearance

Excitatory amino acid transporters (EAATs) remove glutamate from the extracellular space, with EAAT1 and EAAT2 performing important glutamate-uptake functions in glial cells of the central nervous system. After TFB-TBOA blocks EAATs, glutamate clearance slows and extracellular glutamate exposure is prolonged, which can further alter glutamate-receptor activation and neural-network excitability. TFB-TBOA is therefore commonly used to investigate glial glutamate uptake, termination of synaptic signaling, and excitotoxicity.

4.2 Blockade of cGMP–PKG Signaling

cGMP activates cGMP-dependent protein kinase (PKG), which subsequently regulates ion channels, enzymes, and other effector proteins. Rp-8-Br-cGMPS can be used as a cGMP-associated signaling blocker to determine whether a specific cellular effect depends on the cGMP–PKG pathway. Its target is intracellular second-messenger signaling rather than the direct reduction of transmembrane ionic currents.

5 Blockers in Immunoassays

5.1 Endogenous Antibody Interference

(1) Heterophilic Antibodies

Heterophilic antibodies (HAs) can bind immunoglobulins from different animal species through polyreactive interactions. In two-antibody sandwich assays, HAs may simultaneously connect the capture and detection antibodies, generating an abnormal signal when the target antigen is insufficient or even absent; they may also interfere with normal antigen–antibody binding.

(2) Human Anti-Mouse Antibodies

Human anti-mouse antibodies (HAMAs) recognize murine immunoglobulins. When an assay uses mouse monoclonal antibodies, HAMAs may bridge the capture and detection antibodies and produce false-positive results or obstruct binding of the actual antigen and cause falsely low results.

(3) Rheumatoid Factors

Rheumatoid factors (RFs) recognize the Fc region of immunoglobulins and can form nontarget interactions with reagent antibodies in certain immunoassays. The direction of RF interference depends on the assay format, antibody source, and RF level in the sample; it may either increase background or disrupt normal immune-complex formation.

5.2 Polymeric Blockers and Control of HA and RF Interference

The Ab170274 Heterophilic Blocking Reagent is specifically intended to control interference from heterophilic antibodies and rheumatoid factors in immunoassays. Its blocking components reduce nonspecific interactions between endogenous interfering antibodies in the sample and the capture or detection antibodies, thereby decreasing abnormal background, false-positive results, and false-negative results and improving assay reliability.

5.3 Active Blockers and Control of HAMA, RF, and HA Interference

The Ab170291 Active blocker contains components that actively bind interfering factors and targets endogenous sample interference caused by HAMA, RF, and HA, with particularly enhanced blocking activity against heterophilic antibodies. This product can be used on platforms including lateral flow (LF), chemiluminescence immunoassays (CLIA), enzyme immunoassays (EIA), and turbidimetric immunoassays (TIA).

In lateral-flow systems, the blocker can be added to the conjugate-pad or sample-pad treatment solution according to the reagent configuration; in chemiluminescence or enzyme-immunoassay systems, it can be added to magnetic-bead solutions, enzyme-conjugate solutions, or sample solutions; in turbidimetric immunoassays, it can be added to the corresponding working solution. The recommended concentration range is 30–300 µg/ml, and the actual working concentration should be determined through concentration-gradient experiments according to sample type, antibody system, and degree of interference.

5.4 Blocker Screening and Interpretation of Results

The composition and levels of HAs, HAMAs, and RFs differ among samples, and the same blocker may not be suitable for every assay system. The effects of different blockers used individually or in combination can therefore be compared.

If abnormally high values decrease after addition of a blocker while signals from true-positive samples remain stable, the blocker has primarily reduced nonspecific interference; if signals from all samples decrease substantially, whether the blocker is also affecting the normal antigen–antibody reaction should be considered. The objective of immunoassay blocking is to reduce nontarget binding while preserving the true detection reaction, rather than simply decreasing the assay signal.

6 Products

6.1 Products for NaV- and HCN-Channel Blockade Research

6.2 Products for K⁺- and Ca²⁺-Channel Blockade Research

6.3 Products for Blockade of TRP-, PANX1-, Cl⁻-Related, and Membrane-Transport Pathways

6.4 Products for Blocking Interference in Immunoassays

References

[1] Schmalhofer WA, Calhoun J, Burrows R, et al. ProTx-II, a Selective Inhibitor of NaV1.7 Sodium Channels, Blocks Action Potential Propagation in Nociceptors. Mol Pharmacol. 2008;74(5):1476-1484.

[2] Payne CE, Brown AR, Theile JW, et al. A Novel Selective and Orally Bioavailable Nav1.8 Channel Blocker, PF-01247324, Attenuates Nociception and Sensory Neuron Excitability. Br J Pharmacol. 2015;172(10):2654-2670.

[3] Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D. Properties of Ivabradine-Induced Block of HCN1 and HCN4 Pacemaker Channels. J Physiol. 2006.

[4] Candia S, Garcia ML, Latorre R. Mode of Action of Iberiotoxin, a Potent Blocker of the Large Conductance Ca²⁺-Activated K⁺ Channel. Biophys J. 1992;63(2):583-590.

[5] Choe W, Messinger RB, Leach E, et al. TTA-P2 Is a Potent and Selective Blocker of T-Type Calcium Channels in Rat Sensory Neurons and a Novel Antinociceptive Agent. Mol Pharmacol. 2011.

[6] Tsukada S, Iino M, Takayasu Y, Shimamoto K, Ozawa S. Effects of a Novel Glutamate Transporter Blocker TFB-TBOA on Activities of Hippocampal Neurons. Neuropharmacology. 2005;48(4):479-491.

[7] Caufriez A, Lamouroux A, Martin C, et al. Determination of Structural Features That Underpin the Pannexin1 Channel Inhibitory Activity of the Peptide 10Panx1. Bioorg Chem. 2023;138:106612.

[8] Bolstad N, Warren DJ, Nustad K. Heterophilic Antibody Interference in Immunometric Assays. Best Pract Res Clin Endocrinol Metab. 2013;27(5):647-661.

[9] Bartels EM, Ribel-Madsen S. Cytokine Measurements and Possible Interference from Heterophilic Antibodies—Problems and Solutions Experienced with Rheumatoid Factor. Methods. 2013;61(1):18-22.

Major Abbreviations

For more related articles, please see below:

[1] Membrane Transporters and Ion Channels: How Transmembrane Substance Flux Drives Cellular Signaling and Functional Regulation